← All sources
Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
Among 90 people with PAD, 6 months of oral NR versus placebo (trial also included NR+resveratrol arm) improved 6-minute walk distance by a between-group difference of +17.6 m (90% CI +1.8 to +∞) under the prespecified one-sided α; per-protocol adherence ≥75% showed larger walk gains.
Design
- n = 90 PAD participants; double-blind; 6 months
- Arms: NR, NR + resveratrol, placebo (per Nat Commun primary publication)
- Primary: Δ 6-minute walk distance (6MWD) at 6 months
Efficacy (abstract summary)
- ITT-style contrast: NR vs placebo +17.6 m between-group difference on 6MWD (90% CI +1.8 to +∞) with one-sided P < 0.10 per prespecified plan
- ≥75% adherence subgroup: NR +31.0 m vs placebo; NR + resveratrol +26.9 m vs placebo
- Authors state resveratrol did not add detectable benefit beyond NR alone on this endpoint narrative
Evidence hygiene
PAD-enriched efficacy signal—not a primary-prevention walking trial in healthy sedentary adults.
Publication
McDermott MM, et al. Nat Commun. 2024 Aug 12;15:6890. PMID 38871717 (see PubMed-linked publisher corrections).
Outcomes
- Walking Speed% (Percent Change)
- Among participants with ≥75% pill adherence, NR +31.0 m and NR+resveratrol +26.9 m vs placebo on 6-month 6MWD change (abstract).